From Lab to Bedside: How Five Generations of MIRARI® Cold Plasma Technology Led to FDA Clearance
Apr 10, 2026
General Vibronics PR
News
The MIRARI® Cold Plasma System has evolved through five distinct generations over multiple years of engineering — culminating in the 1200-minute GVM2/3.053 version that received FDA 510(k) clearance on November 21, 2024, making it the first handheld cold atmospheric plasma (CAP) device to achieve this regulatory milestone in the United States.[1][2] The device’s evolution from a 240-minute research tool to a fully compliant hospital-grade system mirrors a broader industry shift: the dielectric barrier discharge (DBD) technology segment that powers MIRARI® is now projected to grow at the fastest CAGR in the global cold plasma market through 2034, as clinicians increasingly favor gas-free, portable devices over helium-dependent plasma jets[3].
Developed and patented by General Vibronics Inc. at its headquarters in Tempe, Arizona, the MIRARI® system has undergone a structured evolution across five generations — each expanding the device’s clinical runtime, safety features, and regulatory readiness[4][5].
| Generation | Runtime | Primary Setting | Key Advancement |
|---|---|---|---|
| MIRARI 240 (GVM1) | 240 minutes | Clinical research, basic dermatology | Foundational CAP technology |
| MIRARI 360 (GVM1) | 360 minutes | Research-focused with improved durability | Enhanced battery and plasma array technology |
| MIRARI 480 (GVM1) | 480 minutes | Outpatient clinics and therapy | Dual treatment mode; clinical-level for FDA pathway |
| MIRARI 600 (GVM1) | 600 minutes | Clinics and hospitals | Ergonomic improvements; FDA-ready design |
| MIRARI 1200 (GVM2/3.053) | 1200 minutes | Comprehensive hospital-level, multidisciplinary use | FDA 510(k) cleared; fully compliant system |
Source: General Vibronics / MIRARI Doctor[4]
The early generations (240 and 360) established the foundation for cold plasma therapy, demonstrating reliable acceleration of wound healing, pain reduction, and antimicrobial effects in research settings[4]. The advanced iterations (480, 600, and 1200) progressively expanded clinical indications across wound healing, dermatology, and musculoskeletal pain management — with each version refining hardware, safety systems, and software toward the regulatory requirements that the 1200-minute flagship ultimately met[4].
The fivefold increase in runtime — from 240 to 1200 minutes — addresses a practical clinical reality. Hospital-grade devices must sustain multiple patient treatments per charge cycle without interruption. The 1200-minute capacity enables comprehensive multidisciplinary use across dermatology, wound care, and rehabilitation departments within a single charging cycle[4].
All MIRARI® generations share a common engineering platform — a modular architecture built around three core components[4]:
The rechargeable control box houses an RF/DBD plasma generator that produces therapeutic plasma fields at a resonant frequency of 80 kHz (unipolar)[4][1]. This frequency operates in the kilohertz range — significantly lower than the 4.0 MHz used by the TempSure FlexSure predicate device (K200241) identified in the 510(k) submission — while delivering total power of < 4W and electric field strength of < 80 V/m[1].
An electrode-based CAP emitter measuring 2.50″ × 1.72″ (approximately 29 cm² treatment area), this replaceable component generates thousands of micro-plasma streams across the printed circuit board[4][1].
All current generations use USB-C charging with optimized battery capacity matched to each generation’s runtime requirements. The system is powered by a pair of rechargeable lithium batteries[4][1].
| Specification | Value | Clinical Significance |
|---|---|---|
| RF Frequency | 80 kHz (unipolar) | Optimal tissue penetration |
| Plasma Generation | Dielectric Barrier Discharge (DBD) | Safe, non-thermal plasma; no noble gas required |
| Output Voltage | >700V peak-to-peak | Sufficient ionization for therapeutic efficacy |
| Temperature Limit | Maximum surface: 43°C | Patient comfort and tissue safety |
| UV Emission | >99% UV-A spectrum (310–470 nm) | Antimicrobial effect without harmful radiation |
| Ozone Emission | <40 ppb | Well below UL 867 safety limit |
Source: MIRARI Doctor Technical Specifications[4]
The 43°C maximum surface temperature is a critical safety parameter. Research on DBD plasma has demonstrated that maintaining sub-thermal temperatures allows the biologically active species — particularly reactive oxygen and nitrogen species (ROS/RNS) — to exert their therapeutic effects without causing thermal damage to healthy tissue[6]. A 2020 study on DBD intervention for acute inflammation confirmed that even 3-minute DBD treatments significantly reduced inflammatory cell counts from 2312.17 ± 242.52 to 880.17 ± 89.08, demonstrating that non-thermal plasma achieves biological effects through chemical rather than thermal pathways[7].
The MIRARI® system integrates multiple safety mechanisms that proved essential for FDA clearance[4][1]:
The 510(k) submission documented compliance with IEC 60601-1 Edition 3.2, IEC 60601-1-2:2014 + A1:2020 (electromagnetic compatibility), IEC 60601-2-2:2017 (high-frequency surgical equipment), IEC 62304:2006 + A1:2015 (software lifecycle), and EN ISO 14971:2019 + A11:2021 (risk management)[1].
The MIRARI® system’s reliance on Dielectric Barrier Discharge rather than plasma jet technology positions it within the fastest-growing device segment in the cold plasma market. According to a 2025 industry analysis, while atmospheric pressure plasma jets/handheld devices held the largest revenue share (approximately 52%) in 2024, the DBD panels and pads segment is expected to grow at the fastest CAGR during the forecast period through 2034[3].
The reason is practical: plasma jet devices typically require helium or argon gas — consumables that create ongoing cost and logistical burdens for clinical facilities[8]. The MIRARI® system ionizes ambient air, eliminating noble-gas dependencies entirely[4][1]. As helium supply volatility continues to affect medical gas markets, this gas-free architecture offers hospitals a significant operational advantage.
The broader cold plasma market is expanding rapidly. Estimates place the global market at USD 3.34 billion in 2025, growing to USD 11.14 billion by 2034 at a 14.35% CAGR[3]. Within the healthcare-specific segment, Mordor Intelligence projects growth from USD 2.81 billion (2025) to USD 6.31 billion by 2031 at a 14.62% CAGR[8].
Furthermore, the technology landscape is advancing beyond traditional handheld devices. A February 2026 review in Advanced Materials Technologies surveyed emerging wearable flexible cold atmospheric plasma devices, signaling that the next generation of CAP technology may integrate directly into wearable medical platforms[9]. This underscores the importance of established device platforms like MIRARI® as benchmarks against which future innovations will be measured.
The five-generation journey from a 240-minute research device to an FDA-cleared, 1200-minute hospital platform illustrates the engineering discipline required to translate cold atmospheric plasma from laboratory concept to clinical reality. As the global CAP market accelerates past USD 3 billion and the DBD segment gains momentum, the MIRARI® system’s combination of regulatory clearance, gas-free operation, and modular architecture positions it as a reference point for the handheld cold plasma category. Future coverage will examine clinical outcomes data as post-market studies generate real-world evidence.
The Differences Between Generations and Technical Specifications of the MIRARI® Cold Plasma System
